BTAI (BioXcel Therapeutics) Common Stock: $0.03 Mil (As of Mar. 2026)


BTAI BioXcel Therapeutics Inc BTAI
8 GF Score
Price $0.82
GF Value $0.67
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is BioXcel Therapeutics Common Stock?

BioXcel Therapeutics BTAI -2.42% 8 Common Stock is $0.03 Mil as of Mar. 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Modestly Overvalued). The stock has 5 warning signs investors should review.

BioXcel Therapeutics's quarterly common stock increased from Sep. 2025 ($0.07 Mil) to Dec. 2025 ($0.08 Mil) but then declined from Dec. 2025 ($0.08 Mil) to Mar. 2026 ($0.03 Mil).

BioXcel Therapeutics's annual common stock increased from Dec. 2023 ($0.03 Mil) to Dec. 2024 ($0.05 Mil) and increased from Dec. 2024 ($0.05 Mil) to Dec. 2025 ($0.08 Mil).

BioXcel Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for BioXcel Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioXcel Therapeutics Common Stock Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.03 0.05 0.08

BioXcel Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.07 0.08 0.03
BTAI
8GF Score
BioXcel Therapeutics Inc BTAI
Common Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioXcel Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.03 Mil mean?
BioXcel Therapeutics (BTAI) has a Common Stock of $0.03 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BioXcel Therapeutics and its competitors.
Is BioXcel Therapeutics' Common Stock too high?
BioXcel Therapeutics' current Common Stock is $0.03 Mil. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Common Stock compare to IXHL and SCYX?
BioXcel Therapeutics' Common Stock of $0.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on BioXcel Therapeutics and its competitors. BioXcel Therapeutics's current Common Stock is $0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $0.82 — trading 22.1% above its estimated fair value. The current Common Stock is $0.03 Mil. BioXcel Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Common Stock is $0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioXcel Therapeutics (BTAI) Overvalued in 2026?

Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued. The current stock price of $0.82 is trading 22.1% above its estimated GF Value™ of $0.67. GuruFocus considers BioXcel Therapeutics to be Modestly Overvalued.

Key valuation signals for BTAI:

  • Common Stock: $0.03 Mil
  • GF Value™: $0.67 vs. price of $0.82 (22.1% above fair value)
  • GF Score™: 8/100 with 5 warning signs

No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioXcel Therapeutics Business Description

Other Exchanges BX20:Germany
Address 555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score

Get the complete analysis for BTAI

Common Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.82
Price
$0.67
GF Value